LYZ siRNA (Human)
Cat# MBS827232-15nmol
Size : 15nmol
Brand : MyBiosource
Contact local distributor :
Phone : +1 850 650 7790
LYZ siRNA – Lysozyme C (Human)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS827232MBS827232 is an siRNA targeting LYZ. Also known as LYZ siRNA (Human). Reactive in Human. Host: Synthetic. siRNA to inhibit LYZ expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
LYZ, siRNA
Full Product Name
LYZ siRNA (Human)
Product Gene Name
LYZ sirna
Product Synonym Names
LZM; Lysozyme C; 1.4-beta-N-acetylmuramidase C
Host
Synthetic
Species Reactivity
Human
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
LYZ siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
16,537 Da
OMIM
105200
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LYZ gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for LYZ sirna
RNA Interference (RNAi)
Other Notes
Small volumes of LYZ sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for LYZ. It may not necessarily be applicable to this product.
NCBI Official Full Name
lysozyme C
NCBI Official Synonym Full Names
lysozyme
NCBI Official Symbol
LYZ
NCBI Official Synonym Symbols
LZM
UniProt Protein Name
Lysozyme C
UniProt Synonym Protein Names
1,4-beta-N-acetylmuramidase C
UniProt Gene Name
LYZ
UniProt Synonym Gene Names
LZM
UniProt Entry Name
LYSC_HUMAN
NCBI Protein Information
lysozyme C
NCBI Summary for LYZ
This gene encodes human lysozyme, whose natural substrate is the bacterial cell wall peptidoglycan (cleaving the beta[1-4]glycosidic linkages between N-acetylmuramic acid and N-acetylglucosamine). Lysozyme is one of the antimicrobial agents found in human milk, and is also present in spleen, lung, kidney, white blood cells, plasma, saliva, and tears. The protein has antibacterial activity against a number of bacterial species. Missense mutations in this gene have been identified in heritable renal amyloidosis. [provided by RefSeq, Oct 2014]
Show more UniProt Comments for LYZ
LYZ: Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte- macrophage system and enhance the activity of immunoagents. Defects in LYZ are a cause of amyloidosis type 8 (AMYL8); also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. Belongs to the glycosyl hydrolase 22 family.
Protein type: EC 3.2.1.17; Hydrolase; Secreted; Vesicle; Secreted, signal peptide; Endoplasmic reticulum
Chromosomal Location of Human Ortholog: 12q15
Cellular Component: extracellular space; extracellular region
Molecular Function: identical protein binding; lysozyme activity
Biological Process: retinal homeostasis; metabolic process; cytolysis; defense response to bacterium; inflammatory response
Disease: Amyloidosis, Familial Visceral
Show more Protein type: EC 3.2.1.17; Hydrolase; Secreted; Vesicle; Secreted, signal peptide; Endoplasmic reticulum
Chromosomal Location of Human Ortholog: 12q15
Cellular Component: extracellular space; extracellular region
Molecular Function: identical protein binding; lysozyme activity
Biological Process: retinal homeostasis; metabolic process; cytolysis; defense response to bacterium; inflammatory response
Disease: Amyloidosis, Familial Visceral
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with LYZ sirna
| Reference Product | PubMed Publications |
|---|---|
| LTF sirna | >3 publications with LYZ and LTF |
| SPI1 sirna | >2 publications with LYZ and SPI1 |
| GSN sirna | >1 publications with LYZ and GSN |
Pathways associated with LYZ sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| Amyloids Pathway antibodies | Amyloids Pathway Diagram |
| C-MYB Transcription Factor Network Pathway antibodies | C-MYB Transcription Factor Network Pathway Diagram |
| Disease Pathway antibodies | Disease Pathway Diagram |
| Salivary Secretion Pathway antibodies | Salivary Secretion Pathway Diagram |
| Salivary Secretion Pathway antibodies | Salivary Secretion Pathway Diagram |
Diseases associated with LYZ sirna
| Disease Name | Pubmed Publications |
|---|---|
| Inflammation Antibodies | >14 publications with LYZ and Inflammation |
| Necrosis Antibodies | >8 publications with LYZ and Necrosis |
| Cardiovascular Diseases Antibodies | >7 publications with LYZ and Cardiovascular Diseases |
| Hypertension Antibodies | >2 publications with LYZ and Hypertension |
| Heart Diseases Antibodies | >2 publications with LYZ and Heart Diseases |
| Neoplasms, Experimental Antibodies | >2 publications with LYZ and Neoplasms, Experimental |
| Kidney Diseases Antibodies | >2 publications with LYZ and Kidney Diseases |
| Fibrosis Antibodies | >2 publications with LYZ and Fibrosis |
| Autoimmune Diseases Antibodies | >2 publications with LYZ and Autoimmune Diseases |
| Nervous System Diseases Antibodies | >2 publications with LYZ and Nervous System Diseases |
Organs/Tissues associated with LYZ sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >33 publications with LYZ and Blood |
| Bone Antibodies | >8 publications with LYZ and Bone |
| Heart Antibodies | >8 publications with LYZ and Heart |
| Vascular Antibodies | >8 publications with LYZ and Vascular |
| Intestine Antibodies | >8 publications with LYZ and Intestine |
| Kidney Antibodies | >7 publications with LYZ and Kidney |
| Liver Antibodies | >7 publications with LYZ and Liver |
| Muscle Antibodies | >5 publications with LYZ and Muscle |
| Lymph Node Antibodies | >4 publications with LYZ and Lymph Node |
| Brain Antibodies | >4 publications with LYZ and Brain |